Dengue Vaccines Market
Report ID: SQMIG35I3043
Report ID: SQMIG35I3043
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3043 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
170
|Figures:
79
Global Dengue Vaccines Market size was valued at USD 423.18 Million in 2024 and is poised to grow from USD 481.16 Million in 2025 to USD 1343.91 Million by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).
Increased numbers of rabid mosquitoes in tropical areas around the world is increasing the need for preventative measures such as vaccination. There have been outbreaks of election fatigue over the past 20 years in countries across Southeast Asia, Latin America and Asia. Governments around the world have responded by prioritising vaccinations as a matter of national emergency. The current dengue vaccines market trends includes Takeda's "Qdenga," Sanofi-Pasteur's "Dengvaxia" as well as a number of other candidates. Additional benefits of vaccination include reduced patient morbidity, less strain on hospitals, and maintaining productive economies from the lost thousands of dollars in lost work.
Historically, unsuccessful attempts at vector control and the extensive increase in climatically driven mosquito population growth, have shifted investment towards vaccination. The approval of a number of dengue vaccines from regulatory agencies across the world (e.g. in 2015), have been used as justification to advocate for additional vaccination campaigns in countries such as Brazil, Philippines and Malaysia. In addition to the high incidence of dengue fever, the second most important driver for the growth of the global dengue vaccines market has been the increasing access and innovation within the partnership ecosystem that supports the funding of research and development, as well as accelerating the distribution of new products.
The delivery of funding to GAVI (Global Alliance For Vaccine Immunisation) through WHO prequalification of Qdenga enabled the purchase of Qdenga and increased the overall market size from countries endemic for the dengue virus. An increase in the number of people in the middle class in dengue endemic cities is leading to increased willingness to pay for privately administered dengue vaccines, which has led to manufacturers developing and introducing tiered pricing for each category of people.
As a result of these factors, there are opportunities for companies in Brazil and India to produce locally manufactured vaccines, therefore, decreasing their reliance on imported products and decreasing their total expenditures. These factors create a continuous cycle of increased uptake of dengue vaccines and increased revenue opportunities for both private sector manufacturers and government entities through the formalised use of both subsidies and the private market.
How is AI-driven Data Analytics Shaping the Dengue Vaccine Market's R&D and Rollout?
Data analytics powered by AI is revolutionizing dengue vaccines market growth development using vast epidemiological and genomic databases, creating actionable insights for researchers. Researchers utilize machine learning models to identify areas of current virus serotype circulation, define potential outbreak hotspots, and create immune signatures with antigen design guidance. Researchers use real-time surveillance to support algorithm development by enabling prioritized trial site locations, short enrollment durations, and improved safety evaluation processes.
In addition, this new approach streamlines vaccine manufacturing; predictive models can predict vaccine demand and better optimize scaling of batches to reduce wasted product and expedite distribution. This combined use of AI-based tools creates a tighter feedback loop between data collected in the field and laboratory-based studies; therefore, research timelines for vaccine development are shortened while still being cost-effective, primarily due to the high incidence of dengue disease observed in 2025.
In June 2024, Takeda announced the introduction of its new AI-enabled vaccine deployment platform that integrates climate, travel, and serotype data for same-day rollout planning to facilitate global expansion into new dengue vaccines market share.
Market snapshot - (2026-2033)
Global Market Size
USD 423.18 Million
Largest Segment
Live Attenuated Vaccines
Fastest Growth
Recombinant Vaccines
Growth Rate
13.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global dengue vaccines market is segmented by vaccine type, indication, age group, end user, distribution channel, dosage schedule and region. Based on vaccine type, the market is segmented into live attenuated vaccines, recombinant vaccines and other vaccine technologies. Based on indication, the market is segmented into primary dengue prevention and secondary dengue prevention. Based on age group, the market is segmented into pediatric population and adult population. Based on end user, the market is segmented into hospitals, vaccination centers, public health programs and others. Based on distribution channel, the market is segmented into government procurement, hospital pharmacies, retail pharmacies and others. Based on dosage schedule, the market is segmented into single-dose vaccines and multi-dose vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What Role Does Live Attenuated Vaccines Play in Shaping the Dengue Vaccines Market?
Live-attenuated vaccines are the largest segment in terms of sales. They offer single-shot formulations against the same disease that provide long-term immunity (vaccine-resistant strains) and use a natural process (i.e., viral replication) to generate a full range of immune response. Their proven clinical track record and effectiveness lessen the risk for manufacturers and provide greater confidence in developer and provider acceptance of the product (i.e., increased demand). Because they are so reliable, they have become a preferred basis for developers as well as procurement agencies and as a result have gained a significant share of the total market. In addition, these platforms can quickly be scaled up to meet the increased need generated by epidemics and can be ready in a timely manner to the customer, thereby reinforcing their position as the leader in the market.
Recombinant vaccines will be the fastest-growing vaccine segment as a result of the advancements made in molecular engineering to create more targeted antigens, improving overall safety and adapting to vaccine-hesitant populations. Innovative technologies are also generating more capital investment and speeding up the development of new products in the pipeline and expanding indications and dose administration options. The momentum created by these factors will be further enhanced by the continued emergence of new recombinant product launches which will expand the market and create further opportunities for manufacturers to gain market share through innovation and differentiation.
How Does the Pediatric Population Influence Market Dynamics for Dengue Vaccines?
Governments and non-governmental organisations (NGOs) have prioritised development of an appropriate dengue vaccine for the pediatric population. Children have the greatest burden of disease in endemic areas; therefore, the development of a vaccine for use during early childhood will enable the distribution of vaccines according to existing childhood immunisation schedules and provide for efficient vaccine delivery methods that will increase the likelihood of high coverage. Vaccine development will be oriented towards making products suitable for the pediatric population in terms of dosing and safety, thus making up a significant portion of market growth; growing parental confidence in existing childhood immunisation programmes will help to ensure the continued usage of vaccines and encourage manufacturers to invest in paediatric formulations.
The adult population is growing at the fastest rate as a result of increasing travel, occupational exposure to dengue, and demand for either a booster dose or for first-time immunisation against dengue. Awareness campaigns targeting working-aged adults are on the rise as insurers begin to cover adult immunisations, thus expanding the potential market. The increase in the number of immunised adults creates new revenue opportunities, encouraging developers to seek to expand the indications of dengue vaccine to include additional age ranges.
To get detailed segments analysis, Request a Free Sample Report
The dominance of the Asia Pacific region in the global dengue vaccines market is due to a number of epidemiological, regulatory, and commercial factors. It has a significant burden of dengue cases, which is a factor in helping the government create a path (or procedure) for vaccine registration as well as include immunization in their public health agenda. Other reasons include robust research and development (R&D) ecosystems that exist in Japan and South Korea, which support the development of novel vaccine technologies, and established pharmaceutical manufacturing hubs that can support scaling up production quickly. Additionally, collaboration between universities, biotech companies, and multinational corporations in the region has greatly accelerated the clinical development and commercial introduction of vaccines into the marketplace. Public health campaigns and increasing public knowledge are additional drivers of demand for vaccines, which cements the Asia Pacific's position as the leader in the Dengue Vaccines market. In other words, the strong infrastructure supporting the distribution of vaccines (supporting the establishment of the manufacturer's ability to manufacture) and expanding digital health platforms will enable real-time surveillance of dengue cases and target the most at-risk individuals for the delivery of vaccines, thereby establishing the Asia Pacific's role as the primary driver of global market momentum.
Dengue vaccines market outlook in Japan benefits from a strong regulatory environment that emphasizes rigorous safety assessments while offering accelerated pathways for high‑impact vaccines. The advanced biotech sector in Japan, coupled with close collaboration between government agencies and research universities, fuels continuous innovation. Robust health‑care financing mechanisms ensure broad reimbursement coverage, and public health campaigns raise awareness, driving steady uptake among at‑risk populations. Additionally, integration of digital health records supports precise tracking of vaccination outcomes, reinforcing confidence among clinicians and patients alike.
Dengue vaccines market forecast in South Korea is propelled by a proactive public health policy that prioritizes emerging infectious disease preparedness. Cutting‑edge vaccine research institutions in South Korea collaborate closely with multinational firms to expedite development pipelines. Comprehensive national health insurance schemes provide cost‑effective access, while government‑sponsored awareness programmes educate communities about vector control and immunisation benefits, fostering a receptive market environment for new dengue vaccines. These strategic initiatives collectively enhance domestic manufacturing capacity and position South Korea as a regional hub for vaccine distribution.
European growth is supported by the integration of public health, regulatory harmonization, and increased awareness of the geographic spread of dengue. The establishment of collaborative frameworks, such as those among EU health authorities, has expedited the authorization of dengue vaccines through the establishment of streamlined processes for entry into the market across member states. Substantial investment in next-generation dengue vaccine candidates is also being made via public-private partnerships and through the establishment of advanced research platforms. Additionally, the use of centralised procurement mechanisms creates economies of scale. Increased travel-related tourism and climate-driven vector migration has led to an increase in the perceived risk associated with dengue. As a result, governments have begun to include dengue vaccination as a part of their broader preparedness plans for infectious diseases. Strong reimbursement systems and patient advocacy groups further increase the demand for vaccination and ensure that vaccines are available to patients in the region. In addition to this, the introduction of cross-border data-sharing initiatives allows health authorities to improve their ability to target vaccination campaigns. The combination of science, policy, and market readiness provides a strong foundation for the continued advancement of the Europe dengue vaccine market.
Dengue vaccines market regional outlook in Germany enjoys a leadership position due to its sophisticated health‑care infrastructure and proactive disease‑surveillance network. The country’s strong pharmaceutical manufacturing base supports efficient production and distribution of approved vaccines. Collaborative research institutes work closely with industry to advance clinical studies, while robust reimbursement policies guarantee broad patient access. Public health campaigns emphasizing vector control complement immunisation efforts, reinforcing Germany’s status as a central hub for dengue vaccine adoption across Europe.
Dengue vaccines market regional foercast in United Kingdom is expanding rapidly, driven by an integrated approach that combines cutting‑edge research with dynamic public health initiatives. The National Health Service provides a comprehensive reimbursement framework that facilitates swift uptake of new vaccines. Partnerships between academic centers and biotech firms accelerate innovation pipelines, while targeted awareness programmes educate travelers and high‑risk communities about prevention. This synergistic environment positions the United Kingdom as a leading catalyst for growth in the European dengue vaccine landscape.
Dengue vaccines market penetration in France is emerging as a focal point for vaccine introduction, supported by a comprehensive public health strategy that emphasizes preventive care. Strong collaboration between regional health agencies and vaccine manufacturers streamlines regulatory approval and market access. The national insurance system ensures that approved dengue vaccines are reimbursed, encouraging clinician recommendation. Educational outreach targeting both urban and rural populations raises awareness of dengue risks, laying the groundwork for broader adoption as disease incidence rises.
North America continues to solidify its dominance in the dengue vaccine market thanks to a unique public health environment that includes strong scientific capabilities; significant public health investment; and an agile regulatory environment that allows for fast-tracked vaccine approvals. The United States has one of the largest research university networks and a variety of biotech hubs that facilitate innovative vaccine design. The federal government provides extensive funding for both large-scale clinical trials and post-licensing surveillance of vaccines. Canada has an integrated healthcare system with a focus on prevention, which enables the incorporation of new dengue vaccines into routine immunization schedules when the risk is identified. Cross-border collaborations create synergy through the exchange of information related to vector distributions and disease prevalence; this information is used to develop focused outreach efforts in communities at high risk for contracting dengue. Finally, the combination of high levels of insurance coverage and the proactive participation of physicians will promote widespread acceptance of dengue vaccines in North America; thus making it a leader in developing solutions for the prevention of dengue. The continued focus on public-private partnerships will facilitate the expedited translation of scientific developments into commercially available vaccine products, further enhancing the region's competitive position in regard to dengue vaccine development and delivery.
Dengue vaccines industry in the United States is bolstered by a sophisticated clinical research infrastructure and a high degree of collaboration among federal agencies, academic centers, and industry partners. The expedited approval pathways provided by regulatory authorities encourage rapid market entry for innovative candidates. Comprehensive health‑insurance coverage ensures patient access, while targeted public health campaigns raise awareness among travelers and residents in endemic‑prone regions. These elements collectively drive robust demand and sustain a dynamic market environment.
Dengue vaccines industry trends in Canada benefits from a publicly funded health‑care system that prioritizes preventive immunisation and ensures equitable access across provinces. Strong ties between national research institutes and biotech firms expedite vaccine development and facilitate knowledge transfer. Provincial health authorities integrate dengue vaccination recommendations into broader vector‑control strategies, supported by community outreach programmes that educate at‑risk populations. This coordinated approach enhances vaccine uptake and positions Canada as a proactive participant in regional disease‑prevention initiatives.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Urbanization and Mosquito Breeding
Enhanced Public Health Funding
Variable Vaccine Acceptance Across Regions
Complex Cold Chain Logistics
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global dengue vaccine market is characterized by a limited number of commercialized vaccines, ongoing late-stage clinical development programs, and increasing collaboration between vaccine manufacturers, government agencies, and public-health organizations. Market leaders such as Takeda and Sanofi continue to expand access through regulatory approvals and immunization programs, while regional developers are pursuing localized manufacturing strategies to improve affordability and supply security. Recent industry developments include the approval of Brazil's single-dose Butantan-DV vaccine and large-scale production initiatives aimed at strengthening dengue prevention efforts across endemic regions.
Top Player’s Company Profile
Recent Developments in the Dengue Vaccines Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the primary driver is the rising dengue incidence fueled by rapid urbanization, while a major restraint is the complex cold‑chain logistics required for vaccine delivery; Asia Pacific dominates the market, largely because live attenuated vaccines hold the largest share of sales, and a second driver is the growing partnership ecosystem that accelerates funding, distribution and local production, further expanding uptake. AI‑driven analytics also streamline R&D and forecasting, shortening trial cycles and improving manufacturing efficiency, which supports the market’s rapid growth. Enhanced public health funding further fuels expansion.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 423.18 Million |
| Market size value in 2033 | USD 1343.91 Million |
| Growth Rate | 13.7% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Dengue Vaccines Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Dengue Vaccines Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Dengue Vaccines Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Dengue Vaccines Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Dengue Vaccines Market size was valued at USD 423.18 Million in 2024 and is poised to grow from USD 481.16 Million in 2025 to USD 1343.91 Million by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).
The competitive landscape is shaped by a few approved products and emerging candidates, with manufacturers leveraging partnerships and regional production to expand access. Takeda’s Qdenga and Sanofi’s Dengvaxia dominate current sales, while the Brazil‑Butantan partnership on Butantan‑DV illustrates a strategy of local manufacturing and government collaboration to meet endemic demand. Recent moves include Brazil’s approval of a nationally produced single‑dose vaccine slated for 2026 rollout, reflecting a push for cost‑effective, region‑specific solutions. 'Takeda Pharmaceutical Company Limited', 'Sanofi S.A.', 'Merck & Co., Inc.', 'Pfizer Inc.', 'Moderna, Inc.', 'BioNTech SE', 'GlaxoSmithKline plc', 'Johnson & Johnson', 'Butantan Institute', 'Panacea Biotec Limited', 'Serum Institute of India Pvt. Ltd.', 'Bharat Biotech International Limited', 'Biological E. Limited', 'Emergent BioSolutions Inc.', 'Valneva SE', 'SK bioscience Co., Ltd.', 'Intravacc B.V.', 'Codagenix, Inc.', 'Themis Bioscience GmbH', 'Vabiotech'
Rapid growth of densely populated cities creates abundant breeding sites for Aedes mosquitoes, leading to more frequent dengue outbreaks. Health authorities respond by prioritizing preventive measures, and the heightened awareness among populations drives demand for effective vaccination solutions. Consequently, pharmaceutical companies experience stronger incentives to develop and distribute dengue vaccines, accelerating market expansion as they seek to address the escalating public health challenge presented by expanding urban environments. These conditions also encourage governments to allocate resources toward immunisation programmes, further solidifying the market trajectory toward sustained growth.
Next Generation Recombinant Platforms: The industry is shifting toward recombinant DNA and viral‑vector technologies that promise enhanced immunogenicity while minimizing reactogenicity. These platforms enable modular vaccine design, allowing rapid incorporation of emerging dengue serotype variants and streamlined scale‑up in manufacturing. By leveraging well‑established platform expertise, developers can reduce time‑to‑market, improve safety perceptions among clinicians, and align with global regulatory expectations for standardized production, ultimately expanding market access and fostering broader adoption in endemic regions and reinforcing public health initiatives worldwide.
Why does Asia Pacific Dominate the Global Dengue Vaccines Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
